title: Antibody positron emission tomography imaging in anticancer drug development.
abstract: More than 50 monoclonal antibodies (mAbs), including several antibody-drug conjugates, are in advanced clinical development, forming an important part of the many molecularly targeted anticancer therapeutics currently in development. Drug development is a relatively slow and expensive process, limiting the number of drugs that can be brought into late-stage trials. Development decisions could benefit from quantitative biomarkers, enabling visualization of the tissue distribution of (potentially modified) therapeutic mAbs to confirm effective whole-body target expression, engagement, and modulation and to evaluate heterogeneity across lesions and patients. Such biomarkers may be realized with positron emission tomography imaging of radioactively labeled antibodies, a process called immunoPET. This approach could potentially increase the power and value of early trials by improving patient selection, optimizing dose and schedule, and rationalizing observed drug responses. In this review, we summarize the available literature and the status of clinical trials regarding the potential of immunoPET during early anticancer drug development.
authors.affiliation: Laetitia E. Lamberts, Anton G.T. Terwisscha van Scheltinga, Marjolijn N. Lub-de Hooge, Carolien P. Schröder, Jourik A. Gietema, Adrienne H. Brouwers, and Elisabeth G.E. de Vries, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; and Simon P. Williams, Genentech, South San Francisco, CA.
authors.forename: Laetitia E
authors.initials: LE
authors.lastname: Lamberts
authors.affiliation: Laetitia E. Lamberts, Anton G.T. Terwisscha van Scheltinga, Marjolijn N. Lub-de Hooge, Carolien P. Schröder, Jourik A. Gietema, Adrienne H. Brouwers, and Elisabeth G.E. de Vries, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; and Simon P. Williams, Genentech, South San Francisco, CA.
authors.forename: Simon P
authors.initials: SP
authors.lastname: Williams
authors.affiliation: Laetitia E. Lamberts, Anton G.T. Terwisscha van Scheltinga, Marjolijn N. Lub-de Hooge, Carolien P. Schröder, Jourik A. Gietema, Adrienne H. Brouwers, and Elisabeth G.E. de Vries, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; and Simon P. Williams, Genentech, South San Francisco, CA.
authors.forename: Anton G T
authors.initials: AG
authors.lastname: Terwisscha van Scheltinga
authors.affiliation: Laetitia E. Lamberts, Anton G.T. Terwisscha van Scheltinga, Marjolijn N. Lub-de Hooge, Carolien P. Schröder, Jourik A. Gietema, Adrienne H. Brouwers, and Elisabeth G.E. de Vries, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; and Simon P. Williams, Genentech, South San Francisco, CA.
authors.forename: Marjolijn N
authors.initials: MN
authors.lastname: Lub-de Hooge
authors.affiliation: Laetitia E. Lamberts, Anton G.T. Terwisscha van Scheltinga, Marjolijn N. Lub-de Hooge, Carolien P. Schröder, Jourik A. Gietema, Adrienne H. Brouwers, and Elisabeth G.E. de Vries, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; and Simon P. Williams, Genentech, South San Francisco, CA.
authors.forename: Carolien P
authors.initials: CP
authors.lastname: Schröder
authors.affiliation: Laetitia E. Lamberts, Anton G.T. Terwisscha van Scheltinga, Marjolijn N. Lub-de Hooge, Carolien P. Schröder, Jourik A. Gietema, Adrienne H. Brouwers, and Elisabeth G.E. de Vries, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; and Simon P. Williams, Genentech, South San Francisco, CA.
authors.forename: Jourik A
authors.initials: JA
authors.lastname: Gietema
authors.affiliation: Laetitia E. Lamberts, Anton G.T. Terwisscha van Scheltinga, Marjolijn N. Lub-de Hooge, Carolien P. Schröder, Jourik A. Gietema, Adrienne H. Brouwers, and Elisabeth G.E. de Vries, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; and Simon P. Williams, Genentech, South San Francisco, CA.
authors.forename: Adrienne H
authors.initials: AH
authors.lastname: Brouwers
authors.affiliation: Laetitia E. Lamberts, Anton G.T. Terwisscha van Scheltinga, Marjolijn N. Lub-de Hooge, Carolien P. Schröder, Jourik A. Gietema, Adrienne H. Brouwers, and Elisabeth G.E. de Vries, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; and Simon P. Williams, Genentech, South San Francisco, CA. e.g.e.de.vries@umcg.nl.
authors.forename: Elisabeth G E
authors.initials: EG
authors.lastname: de Vries
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000378:metabolism / Q000627:therapeutic use*; D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D018579:Patient Selection; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D014018:Tissue Distribution; D016896:Treatment Outcome; D051598:Whole Body Imaging
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals